| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MEP1b |
| Uniprot No | Q16820 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-652aa |
| 氨基酸序列 | MDLWNLSWFL FLDALLVISG LATPENFDVD GGMDQDIFDI NEGLGLDLFE GDIRLDRAQI RNSIIGEKYR WPHTIPYVLE DSLEMNAKGV ILNAFERYRL KTCIDFKPWA GETNYISVFK GSGCWSSVGN RRVGKQELSI GANCDRIATV QHEFLHALGF WHEQSRSDRD DYVRIMWDRI LSGREHNFNT YSDDISDSLN VPYDYTSVMH YSKTAFQNGT EPTIVTRISD FEDVIGQRMD FSDSDLLKLN QLYNCSSSLS FMDSCSFELE NVCGMIQSSG DNADWQRVSQ VPRGPESDHS NMGQCQGSGF FMHFDSSSVN VGATAVLESR TLYPKRGFQC LQFYLYNSGS ESDQLNIYIR EYSADNVDGN LTLVEEIKEI PTGSWQLYHV TLKVTKKFRV VFEGRKGSGA SLGGLSIDDI NLSETRCPHH IWHIRNFTQF IGSPNGTLYS PPFYSSKGYA FQIYLNLAHV TNAGIYFHLI SGANDDQLQW PCPWQQATMT LLDQNPDIRQ RMSNQRSITT DPFMTTDNGN YFWDRPSKVG TVALFSNGTQ FRRGGGYGTS AFITHERLKS RDFIKGDDVY ILLTVEDISH LNSTQIQLTP APSVQDLCSK TTCKNDGVCT VRDGKAECRC QSGEDWWYMG ERCEKRGSTR DT |
| 预测分子量 | 73 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇与MEP1b重组蛋白相关的代表性文献摘要信息：
1. **文献名称**: "Recombinant expression and characterization of meprin β in inflammatory bowel disease"
**作者**: Jefferson T, et al.
**摘要**: 研究报道了人源MEP1b重组蛋白在大肠杆菌中的可溶性表达及纯化，发现其在结肠炎模型小鼠肠道炎症反应中通过调节细胞因子IL-6的活性加剧黏膜损伤，提示其作为炎症性肠病治疗靶点的潜力。
2. **文献名称**: "Proteolytic processing of amyloid-β by meprin β: Implications for Alzheimer's disease"
**作者**: Bien J, et al.
**摘要**: 通过HEK293细胞表达重组MEP1b，证实该金属蛋白酶可切割淀粉样蛋白Aβ42生成神经毒性片段，揭示了MEP1b在阿尔茨海默病病理中的潜在作用机制，为开发抑制其活性的药物提供依据。
3. **文献名称**: "Structural insights into the activation mechanism of meprin β by pro-inflammatory cytokines"
**作者**: Schütte A, et al.
**摘要**: 利用昆虫细胞系统制备活性重组MEP1b蛋白，结合冷冻电镜解析其与TNF-α的复合物结构，阐明炎症因子通过诱导构象变化激活蛋白酶活性的分子基础，为调控MEP1b功能提供结构生物学证据。
注：以上文献信息为示例性内容，实际文献需通过PubMed或Web of Science以"MEP1B recombinant protein"为关键词检索获取。若研究领域较新，建议补充预印本平台(如bioRxiv)的最新成果。
**Background of MEP1b Recombinant Protein**
Meprin 1β (MEP1b), a member of the astacin family of metalloproteases, plays a critical role in extracellular matrix (ECM) remodeling and cellular signaling. It is a subunit of meprin proteases, which exist as homo- or hetero-oligomeric complexes. MEP1b specifically pairs with the α subunit (MEP1a) to form meprin A, a membrane-bound or secreted protease. Unlike MEP1a, which contains a transmembrane domain, MEP1b is anchored via a glycosylphosphatidylinositol (GPI) linkage, influencing its localization and substrate accessibility.
Meprins are highly expressed in the kidney, intestine, and immune cells, where they regulate processes like inflammation, fibrosis, and cancer progression. MEP1b contributes to ECM degradation by cleaving components such as collagen, laminin, and proteoglycans. It also processes bioactive molecules like cytokines (e.g., interleukin-1β) and growth factors, modulating immune responses and tissue repair. Dysregulation of MEP1b is linked to pathological conditions, including renal fibrosis, inflammatory bowel disease, and tumor metastasis.
Recombinant MEP1b protein is engineered for research and therapeutic applications. Produced in mammalian or insect cell systems, it retains post-translational modifications essential for activity. Purification typically involves affinity chromatography, yielding high-purity enzymatically active protein. Studies utilize recombinant MEP1b to investigate substrate specificity, inhibitor screening, and mechanistic roles in diseases. Its potential as a therapeutic target or biomarker drives ongoing research, particularly in fibrosis and cancer.
In summary, MEP1b recombinant protein serves as a vital tool for understanding protease-mediated pathways and developing interventions for ECM-related disorders.
×
